PTCH1, a receptor of Hedgehog signaling pathway, is correlated with metastatic potential of colorectal cancer by You, Sihong et al.
Upsala Journal of Medical Sciences. 2010; 115: 169–175
ORIGINAL ARTICLE
PTCH1, a receptor of Hedgehog signaling pathway, is correlated with
metastatic potential of colorectal cancer
SIHONG YOU
1, JIANNONG ZHOU
2, SENQING CHEN
2, PING ZHOU
2, JINGHUAN LV
1,
XIAO HAN
1 & YUJIE SUN
1,3
1Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, People’s
Republic of China,
2Jiangsu Institute of Cancer Research, Nanjing, People’s Republic of China, and
3Cancer Center,
Nanjing Medical University, Nanjing, People’s Republic of China
Abstract
Background. Approximately 90% of colorectal cancer (CRC) deaths arise from the metastatic dissemination of primary tumors.
It is difﬁcult to predict metastasis of colorectal cancer, especially for patients with the same pathological subtype and
differentiation.
Aims. To identify biomarkers for predicting CRC metastasis.
Patients and methods. We collected 19 primary tumors of CRC with identical pathological subtype, differentiation, and
comparable Dukes’ stages from patients with matched age and gender but completely different prognosis. Patients were
divided into one high-riskand one low-risk groupfor metastasis. Theexpression levels of SHH, PTCH1, and sFRP1, which are
components of the Hedgehog signaling pathway, were determined by real-time reverse transcription polymerase chain reaction
(RT-PCR). To investigate further the correlation between expression level of PTCH1 and metastatic potential of CRC cells,
we compared the mRNA and protein levels of the PTCH1 gene in LoVo cells with high metastatic potential and in HT-29,
SW480, and SW620 cells with low metastatic potential by RT-PCR and ﬂow cytometry.
Results. We found that tumor tissues in the high-risk group for metastasis expressed lower levels of PTCH1 mRNA than did
those in the low-risk group. Similarly, mRNA and protein levels of PTCH1 were inversely correlated with the metastatic
potential of CRC cell lines. Expression levels of SHH and sFRP1 genes did not differ between the two groups.
Conclusion. Our data suggest that PTCH1 might be a potential biomarker that could discriminate CRC with high from that with
low metastatic risk.
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Introduction
Colorectal cancer (CRC) is the second most prevalent
cancer in developed countries and the third most
prevalent cancer in developing nations (1,2). During
the past few decades, the morbidity and mortality of
CRC have increased rapidly in China (3). Although
great progress has been made in the diagnosis and
treatment, such as in colonoscopy (4), chemotherapy
(5), and molecular targeted drugs (6), the 5-year
mortality for people diagnosed with CRC remains
approximately 40% (7). Since approximately 90%
of colorectal cancer deaths arise from the metastatic
dissemination of primary tumors (8,9), it is important
to ﬁnd biomarkers which can predict the risk of
metastasis of colorectal cancer. Although a number
of molecular markers have been found to be possible
prognostic factors, more ‘predictors’ need to be deter-
mined which can identify patients with high risk for
metastasis (10).
Wnt and Hedgehog signaling pathways are both
highly implicated in colonic epithelial homeostasis.
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to gastrointestinal cancers (11). Hedgehog family
ligands include Sonic hedgehog (SHH), Indian
hedgehog (IHH), and Desert hedgehog (DHH)
(12,13). In the absence of Hedgehog ligand, Patched
family receptors (PTCH1 and PTCH2) inhibit ano-
ther membrane receptor Smoothened (SMO), which
leadstotheformationofcytoplasmicglioma-associated
oncogene (GLI) degradation complex. Binding of
Hedgehog to PTCH1 or PTCH2 releases the SMO
signal transducer from Patched-dependent suppres-
sion, which promotes the nuclear accumulation of
full-lengthGLIandleadstoGLI-dependenttranscrip-
tionalactivationoftargetgenes,suchasGLI1,PTCH1,
CCND2, and FOXL1, etc. (13–17). It has been
reported that SHH can promote motility and
invasiveness of gastric cancer cells, suggesting the
involvement of SHH signaling in the metastasis of
gastric cancer (18).
In order to investigate the role of Hedgehog
signaling pathway in the metastasis of colorectal
cancer and ﬁnd biomarkers for predicting meta-
stasis of CRC, we analyzed the expression levels of
several components of Hedgehog signaling path-
way, including SHH (a Hedgehog family ligand),
PTCH1 (a receptor of Hedgehog signaling path-
way), and sFRP1 (a target gene of Hedgehog signal-
ing pathway), in the primary tumors of colorectal
cancers from 8 patients with low risk (no recurr-
ence or metastasis was observed 5 years after the
operation) and 11 patients with high risk for metas-
tasis (metastasis occurred within 2 years after the
operation) by using quantitative real-time reverse
transcription polymerase chain reaction (RT-PCR)
method. All the samples presented identical patho-
logical subtype and differentiation, and the two
groups possessed comparable Dukes’ stage. To
investigate further the relationship between the
expression level of PTCH1 and the metastatic poten-
tial of CRC cells, we compared mRNA and protein
levels of PTCH1 gene in CRC cell lines with
different metastatic potentials by RT-PCR and
ﬂow cytometry.
Materials and methods
Patients and samples
A total of 19 primary CRC tumor tissues with iden-
tical pathological subtype (adenocarcinoma), same
differentiation (Grade 2, moderately differentiated),
and comparable Dukes’ stages were collected from
Jiangsu Institute of Cancer Research between June
2000 and June 2004. The patients were divided into
two groups: patients diagnosed with metastasis within
2 years after the operation were deﬁned as high-risk
group for metastasis, and patients without recurrence
or metastasis in 5 years after resection were deﬁned as
low-risk group for metastasis. None of the patients
received chemotherapy or radiotherapy before oper-
ation. Among the patients, 9 cases were male, and 10
were female. The ages of the patients were from 30 to
73 and average 53.6 ± 12.2 years. The locations of the
primary tumor were 9 at rectum, 4 at sigmoid, 2 at
ascending colon, 2 at cecum, 1 at splenic ﬂexure, and
1 at anal canal. Altogether 12 patients belonged to
Dukes’ B stage and 7 to Dukes’ C stage. The site of
metastases included lung (4 cases), liver (3 cases),
lung and liver (2 cases), lung and bone (1 case), and
ovary (1 case). The mean time interval between the
operation of the primary tumor and the detection of
metastasis was 16 months. The samples were frozen
and stored in liquid nitrogen.
Quantitative real-time RT-PCR
Three components of the Hedgehog signaling path-
way, SHH, PTCH1, and SFRP1, were selected for
quantitative real-time RT-PCR analysis. The refer-
ence sequences for each gene were obtained from the
NCBI Entrez web site. The primer pairs (Table I)
Table I. Sequences of primer pairs.
Genes Primers (5’!3’) Size (bp) GeneBank
SHH F CAATTACAACCCCGACATCATA 194 NM_000193
R CCTCGTAGTGCAGAGACTCCTC
PTCH1 F GGGTGGCACAGTCAAGAACAG 108 NM_000264
R TACCCCTTGAAGTGCTCGTACA
sFRP1 F TCTACTGGCCCGAGATGCTT 147 NM_003012
R TGGCCTCAGATTTCAACTCGTT
b-Actin F GAAATCGTGCGTGACATTAA 179 NM_001101
R AAGGAAGGCTGGAAGAGTG
170 S. You et al.were designed using Primer Express (Applied
Biosystems, CA, USA).
Total RNA was extracted from tissue samples using
TRIZOL
  Reagent (Invitrogen Life Technologies,
CA, USA). First-strand cDNA was synthesized
using ReverTra Ace (TOYOBO, Osaka, Japan)
with 1 mg of total RNA in 20 mL reaction volume,
containing 1   Reverse Transcription Buffer, 1 mM
dNTPs each, 0.5 mM Oligo(dT)20, 10 U RNase
inhibitor, 1 mL ReverTra Ace.
Real-time PCR was carried out on an ABI PRISM
7000 system (Applied Biosystems, CA, US) using
SYBR
  Green Realtime PCR Master Mix
(TOYOBO, Osaka, Japan). PCR products were
detected with melting curve analysis. The ABI
PRISM 7000 SDS software (version 1.0) was used
for the analysis and interpretation of the results.
The reactions included 2 mL cDNA (1:10 dilution),
4 pmol of each primer and the SYBR
  Green Real-
time PCR Master Mix. The ﬁnal reaction volume was
20 mL. PCR was performed under the following
cycling conditions: an initial denaturation step at
95 C for 1 min, followed by 40 cycles of ampliﬁcation
(95 C for 15 s, 60 C for 15 s, and 72 C for 45 s).
Every PCR reaction of each gene and each sample was
done in duplicate.
Real-time PCR data were quantitated using the
cycle threshold (CT) method. b-Actin mRNA was
used as an internal control. The amount of target
genes mRNA in tumor tissue relative to that in paired
self control was calculated as follows:
CT(Tumor or Control)=CT(Target Gene)
                                           CT ( -actin)
Δ
−β
ðEq:1Þ
ΔΔ Δ −Δ CT= CT(Tumor) CT(Control) ðEq:2Þ
ΔΔ -C T Amountof target=2 (19) ðEq:3Þ
Greater 2
–DDCT of a certain gene in a paired tumor
and control samples represents a higher ratio of
mRNA quantity in tumor over control.
Cell culture
LoVo cell line with high metastatic potential and
HT-29, SW480, and SW620 cell lines with low
metastatic potential were obtained from ATCC
(American Type Culture Collection, Manassas, VA,
USA). HT-29, SW480, and LoVo were maintained in
RPMI 1640 (Gibco, CA, USA), supplemented with
10% (v/v) new-born calf serum, and SW620 was
maintained in Leibovitz’s L-15 (Gibco, USA),
supplemented with 10% (v/v) fetal bovine serum.
All media contained streptomycin (100 U/mL) and
penicillin (100 U/mL). The cells were grown at 37 C
in a humidiﬁed 5% CO2 atmosphere.
Wound-healing assay
Wound-healing assays were performed to evaluate
the metastatic potential of CRC cells. HT-29,
SW480, SW620, and LoVo cells were seeded in
12-well plates at a density of 4   10
5 cells/well and
culturedfor12–24huntiltheyreached90%conﬂuence
before scratching across the cell monolayer with a
plastic tip. Cells were then grown in serum-free
medium.Wound-healingwasobservedatevery6hours
within the scrape line, and representative scrape lines
were photographed. Quantiﬁcation of the area was
performed using Image-Pro Plus 4.5, and cell motility
was calculated as follows:
×
(initial wound area - remaining wounded area)
%
initial wound area
ðEq:4Þ
Detection of PTCH1 mRNA by RT-PCR in cell lines
Total RNA was extracted from cells in exponential
growth phase. First-strand cDNA was synthesized
according to the protocol mentioned above. PCR
conditions for PTCH1 gene were 94 C for 5 min;
40 cycles of 94 C for 30 s, 60 C for 30 s, and 72 C for
30 s; and a ﬁnal extension at 72 C for 10 min in a
volume of 50 mL, containing 1   PCR Buffer, 2.5 mL
of cDNA, 0.5 mM of each primer, 0.2 mM dNTPs
each, 1.5 mM magnesium chloride, and 1.25 units of
Taq DNA Polymerase (TaKaRa BioTechnology,
Dalian, China). The PCR products were separated
on 2% (w/v) agarose gels.
Flow cytometry analysis
Rabbit polyclonal to Patched/PTCH primary anti-
body (Abcam, Cambridge, UK) was used to label
PTCH1 protein on CRC cells. Adherent cell mono-
layers were detached by treatment with 0.25% trypsin
and 0.02% EDTA. After ﬁxation in 1% paraformal-
dehyde for 20 minutes, cells were stained with pri-
mary antibody at 1:100 dilutions overnight, at 4 C.
After washing with phosphate-buffered saline (PBS),
the cells were incubated with ﬂuorescein isothio-
cyanate (FITC) conjugated goat anti-rabbit IgG
antibodies (1:100) for 1 h at room temperature in
PTCH1 and metastasis of colorectal cancer 171the dark. Flow cytometry analysis was then performed
on a FACSCalibur (BD Biosciences, San Jose, CA,
USA), and 10,000 events were collected and analyzed
with CellQuest software (BD Biosciences). Base-line
staining was obtained by adding PBS to the cells
instead of primary antibody. Additional negative con-
trols included irrelevant antibodies that conﬁrmed the
speciﬁcity of the staining.
Statistical analysis
Statistical analyses were carried out using the SPSS
program (SPSS, version 11.0, Chicago, IL, USA) and
Microsoft Excel 2003 (Microsoft Corporation, Seat-
tle, USA). Comparison of data between high-risk
group and low-risk group for metastasis utilized
Mann-Whitney U test. For comparison of wound-
healing assay and ﬂow cytometry data between CRC
cells, independent sample t tests were carried out.
Results
Expression levels of PTCH1 in colorectal cancer samples
To identify biomarkers that could discriminate
patients with high risk for metastasis from those
with low risk, we collected 19 primary tumor samples
with identical pathological subtype, same differentia-
tion, and comparable Dukes’ stages from CRC
patients. The patients were divided into one high-
risk and one low-risk group for metastasis. There was
no difference in gender, age, and Dukes’ stage
between the two groups. Expression levels of SHH,
PTCH1, and sFRP1 mRNA in cancer samples were
analyzed with real-time PCR. We found that the
high-risk group had lower levels (P = 0.002) of
PTCH1 mRNA than did the low-risk group
(Figure 1A). However, expression levels of the
SHH and sFRP1 genes did not differ between the
two groups (Figures 1B–C).
Expression level of PTCH1 mRNA in cells with high and
low metastatic potential
To investigate the correlation of expression level of
PTCH1 and metastatic potential of CRC cells fur-
ther, we examined the expression level of PTCH1
mRNA by RT-PCR in LoVo, HT-29, SW480, and
SW620 cells. The metastatic potential of these cells
was determined by wound-healing experiments.
After 18 hours of incubation, LoVo cells ﬁlled
almost 40% of the scratched area compared with
approximately 10% by HT-29, SW480, and SW620
cells (Figures 2A–B). RT-PCR revealed that the
expression level of PTCH1 mRNA was lower in
high metastatic LoVo cells than that in low metastatic
HT-29, SW480, and SW620 cells (Figure 2C).
12
10
8
6
4
2
P
T
C
H
1
 
l
e
v
e
l
s
 
i
n
 
t
u
m
o
r
/
c
o
n
t
r
o
l
S
H
H
 
l
e
v
e
l
s
 
i
n
 
t
u
m
o
r
/
c
o
n
t
r
o
l
s
F
R
P
1
 
l
e
v
e
l
s
 
i
n
 
t
u
m
o
r
/
c
o
n
t
r
o
l
0
-2
N = 11 8
Low risk group High risk group
N = 11 8
Low risk group High risk group
N = 11 8
Low risk group High risk group
Groups
Groups
4
3
2
1
0
-1
Groups
200
100
-100
0
8
17
4
4
2
12
a.
b.
c.
Figure 1. Expression level of a target gene was determined by real-
time PCR. Calculation of statistical difference between high-risk
group and low-risk group utilized Mann-Whitney U test.
172 S. You et al.Expression level of PTCH1 protein in cells with high and
low metastatic potential
The correlation between expression level of PTCH1
protein and metastatic potential of CRC cells was
further investigated in HT-29, SW480, SW620, and
LoVo cells by ﬂow cytometry analysis using an
anti-PTCH1 antibody. As expected, the positive rates
for PTCH1 were signiﬁcantly higher in HT-29,
SW480, and SW620 cells with low metastatic poten-
tial than that in LoVo cells with high metastatic
potential (Figure 3A, 3B).
Discussion
Metastasis is a common event in colorectal cancer,
especially metastasizing to the liver, which leads to a
failure of the therapeutic regimen (8). It is still difﬁcult
to predict metastatic risk of the disease based on
clinical parameters, as colorectal cancers with
identical pathological subtype, differentiation, and
Dukes’ stage could have signiﬁcant differences in
metastatic potential (10). Our study revealed that
PTCH1 expression was inversely correlated with
metastasis of CRC, which suggested that it could be
a potential biomarker for predicting the metastatic risk
of colorectal cancer. The sensitivity and speciﬁcity of
PTCH1 for predicting metastatic risk of colorectal
cancer should be evaluated further in larger samples.
Multiple center co-operation and long-term follow-up
would be necessary to get enough CRC patients
with identical pathological subtype, differentiation,
Dukes’ stage, matched age and gender, but different
metastatic risks.
Hedgehog signaling pathway plays a role in initia-
tion and progression of gastrointestinal cancers. Hedg-
ehog signaling is frequently activated in esophageal,
gastric, and pancreatic cancer (13,20,21). PTCH1, a
receptor of Hedgehog signaling pathway, can suppress
the pathway by inhibiting SMO. Binding of SHH, a
Hedgehog family ligand, to PTCH1 leads to release of
SMO signal transducer and activation of the pathway
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Figure 2. A: HT-29, SW480, SW620, and LoVo cells were seeded in 12-well plates and cultured for 12–24 h until they reached 90%
conﬂuence before scratching across the cell monolayer with a plastic tip. Cells were then grown in serum-free medium. Wound-healing was
observed at every 6 hours within the scrape line, and representative scrape lines were photographed. B: Quantitative analysis of three
independent cell motility experiments with LoVo, HT-29, SW480, and SW620 cells. C: RT-PCR experiments to demonstrate expression
levels of PTCH1 mRNA in the same cell lines.
PTCH1 and metastasis of colorectal cancer 173(13,14). Loss of PTCH1 is known to release the SMO
signal transducer from Patched-dependent suppres-
sion and further activates Gli1 (22). It is reported
that Gli1 up-regulates the expression of Snail, which
is a repressor of E-cadherin gene expression (23–25).
As E-cadherin has been implicated in CRC metastasis
(26), our observation implied that PTCH1 might be
involved in metastasis of colorectal cancer possibly
through affecting the expression of E-cadherin.
SHH signaling has been implicated in the metastasis
of gastric cancer and pancreatic adenocarcinomas
(18,27). Inhibition of SHH signaling could reduce the
tumor burden and metastasis in pancreatic adeno-
carcinomas (27). sFRP1, a target gene of Hedgehog
signaling pathway, together with sFRP2-5, DKK1-4,
and WIF1 genes, encoding secreted-type WNT inhibi-
tors, constitutes the negative regulation system of the
Wnt signaling pathway (28). However, differential
expressions of SHH and sFRP1 were not observed in
thehigh-riskgroupversusthelow-riskgroupformetas-
tasis in this study. These results suggested that the
function of PTCH1 in metastasis of colorectal cancer
could be independent of SHH and sFRP1. It will be
interesting to investigate the mechanisms by which loss
ofPTCH1expressionpromotesthemetastaticpotential
of CRC cells.
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